8-K: Bioxytran Secures A-SUQAR Distribution Deal with Khoury Medical

Bioxytran, Inc. announced a commercial distribution agreement with Khoury Medical LTD for its A-SUQAR dietary supplement, marking a transition to commercial revenue.

Summary

• Bioxytran, Inc. entered into a commercial Distribution Agreement with Khoury Medical LTD on February 10, 2026.
• Khoury Medical will commercialize A-SUQAR, a chewable dietary supplement containing Bioxytran's proprietary partially hydrolyzed guar gum (PHGG) formulation.
• A-SUQAR is intended to support healthy post-meal blood sugar levels, consistent with applicable regulatory requirements.
• The distribution right is initially non-exclusive, limited to pharmacy channels.
• Exclusivity in the marketplace is granted if Khoury Medical reaches purchases of [***] Units of each Product in 2026 or any ensuing year, or for a period of six months upon completion of the purchase of the initial [***] Units of each Product.
• The purchase price for the finished product is [***] per Unit, based on an Ex Works Bangalore, India price, with a minimum order of [***] Units.
• Bioxytran will use a designated OEM manufacturer, allowing it to maintain a capital-efficient commercial model while retaining full ownership of its intellectual property.
• The agreement is structured to apply solely to non-pharmaceutical dietary products, preserving Bioxytran's ability to independently advance and partner its technology for pharmaceutical, antiviral, and other clinical development applications.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive and expected step for Bioxytran, providing initial commercial revenue and market validation for its platform while strategically preserving resources for higher-value pharmaceutical development.

Positives

• Secures a commercial distribution agreement for A-SUQAR, marking Bioxytran's transition from a development-stage organization to a company with recurring commercial revenue.
• Provides real-world market validation for Bioxytran's proprietary carbohydrate-based galectin platform.
• Allows Bioxytran to maintain a capital-efficient commercial model by utilizing a designated OEM and having Khoury Medical lead regulatory registration, marketing, and distribution execution.
• Preserves Bioxytran's ability to independently advance and partner its higher-value pharmaceutical and antiviral development programs.
• The agreement offers potential for earned, volume-based marketplace exclusivity for Khoury Medical, incentivizing sales.
• Recent positive Phase 2 clinical results with ProLectin-M further validate the underlying galectin-targeting science, which underpins both pharmaceutical and nutraceutical applications.

Negatives

• The initial distribution right is non-exclusive, potentially limiting immediate market control or higher revenue share for Bioxytran.
• Specific financial terms like the exact purchase price per unit and exclusivity thresholds are redacted ([***]), making a full financial assessment difficult.
• Khoury Medical is responsible for the collection, remittance, and payment of any and all taxes, charges, levies, assessments, and other fees related to the purchase, sale, importation, or distribution of the Products in the Territory.

Risks

• Risks related to regulatory compliance for the dietary supplement.
• Challenges in commercialization execution by Khoury Medical.
• Uncertainty regarding market acceptance of A-SUQAR.
• Risks associated with clinical development of other Bioxytran products.
• Challenges in intellectual property protection.
• Financing requirements for Bioxytran's broader operations.
• Other factors described in Bioxytran's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Future Outlook

Bioxytran expects initial commercial shipments of A-SUQAR to commence following standard launch preparations. The agreement is anticipated to provide recurring commercial revenue and validate the company's proprietary carbohydrate-based galectin platform, while allowing continued advancement of higher-value pharmaceutical and antiviral programs.

Management Comments

• "This agreement represents an important milestone for Bioxytran as we transition from a development-stage organization to a company with recurring commercial revenue." David Platt, Chief Executive Officer of Bioxytran.
• "A-SUQAR provides real-world market validation of our proprietary carbohydrate-based galectin platform, while preserving our ability to advance higher-value pharmaceutical and antiviral programs." David Platt, Chief Executive Officer of Bioxytran.
• "This collaboration allows us to bring a differentiated, science-informed product with the potential for broader market expansion, subject to applicable agreements and regulatory requirements." Mr. Nassar Khoury, CEO of Khoury Medical LTD.
• "We believe A-SUQAR addresses a meaningful consumer need, and we look forward to building a successful commercial launch together with Bioxytran." Mr. Nassar Khoury, CEO of Khoury Medical LTD.

Industry Context

StockSavvy.ai notes that the dietary supplement market, particularly for blood sugar management, is competitive but growing, driven by increasing health consciousness. Bioxytran's entry with a science-backed, plant-derived PHGG formulation positions it to capture a segment of this market. The strategy of leveraging a distribution partner like Khoury Medical for nutraceuticals while retaining focus on pharmaceutical development is a common approach for biotech companies seeking early revenue streams without diverting significant R&D resources. This dual-track approach allows for market validation of core technology in a less regulated space while pursuing higher-value, longer-term pharmaceutical applications.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Potential for new revenue streams and market validation of Bioxytran's technology, which could positively impact stock value.
• Customers: Introduction of a new dietary supplement, A-SUQAR, aimed at supporting healthy post-meal blood sugar levels.
• Employees: Potential for growth and expansion as the company transitions to a commercial stage.
• Khoury Medical: Gains distribution rights for a new product, expanding its portfolio of plant-derived dietary supplements.

Next Steps

• Khoury Medical to submit a marketing plan for the Products in the Territory at least 90 days before the beginning of each calendar year.
• Khoury Medical to provide quarterly written progress reports on Commercialization activities.
• Initial commercial shipments are expected to commence following completion of standard launch preparations.
• The parties intend to switch from supplying finished products to supplying bulk tablets for bottling in the United States as soon as reasonably possible.

Key Dates

Recommendation

While the distribution agreement is a positive step towards commercialization and validates Bioxytran's platform, the financial impact is not fully disclosed due to redactions. The company remains primarily a development-stage biotech with higher-value pharmaceutical programs still in clinical stages. This agreement provides a revenue stream and market validation but does not fundamentally alter the long-term risk/reward profile associated with its core drug development pipeline. Investors should hold to observe the commercial success of A-SUQAR and further progress in its pharmaceutical programs.

Keywords

Bioxytran, Khoury Medical, A-SUQAR, Dietary Supplement, PHGG, Blood Sugar, Distribution Agreement, Biotechnology, Galectin-targeting, Nutraceuticals, Commercialization, Healthcare